The Influence of Eicosapentaenoic Acid to Arachidonic Acid Ratio on Long-term Cardiovascular Events Following Percutaneous Coronary Intervention.
EPA/AA ratio
cardiovascular event
coronary artery disease
Journal
Internal medicine (Tokyo, Japan)
ISSN: 1349-7235
Titre abrégé: Intern Med
Pays: Japan
ID NLM: 9204241
Informations de publication
Date de publication:
15 Dec 2021
15 Dec 2021
Historique:
pubmed:
22
6
2021
medline:
18
12
2021
entrez:
21
6
2021
Statut:
ppublish
Résumé
Objective The relationship between cardiovascular disease and the serum polyunsaturated fatty acid parameters has been reported. The aim of the present study was to investigate the association between the eicosapentaenoic acid and arachidonic acid (EPA/AA) ratio and long-term cardiovascular events in patients with coronary artery disease. Methods We identified a total of 831 patients who underwent percutaneous coronary intervention and whose EPA/AA ratio was available. The patients were divided into two groups according to their serum EPA/AA ratio (median, 0.29; interquartile range 0.19-0.47): those in the lower quartile of EPA/AA ratios (Low EPA/AA group; n=231) and all other subjects (High EPA/AA group; n=600). The primary endpoints included a composite of cardiovascular death, myocardial infarction, and ischemic stroke. Results Patients in the Low EPA/AA group were significantly younger (66.0±12.6 years vs. 69.9±9.3 years, p<0.001), current smokers (33.3% vs. 22.7%, p=0.002), and had a history of myocardial infarction (20.3% vs. 12.3%, p=0.003). During the follow-up (median, 1,206 days; interquartile range, 654-1,910 days), the occurrence of the primary endpoint was significantly higher in the Low EPA/AA group than in the High EPA/AA group. Of note, the rate of cardiovascular death was significantly higher in the Low EPA/AA group, and the rates of myocardial infarction and stroke tended to be higher. Conclusion A low EPA/AA ratio was associated with long-term adverse cardiovascular events in Japanese patients with coronary artery disease.
Identifiants
pubmed: 34148960
doi: 10.2169/internalmedicine.7336-21
pmc: PMC8758441
doi:
Substances chimiques
Arachidonic Acid
27YG812J1I
Eicosapentaenoic Acid
AAN7QOV9EA
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3865-3871Références
Lancet. 1978 Jul 15;2(8081):117-9
pubmed: 78322
Prostaglandins Leukot Essent Fatty Acids. 2019 Jan;140:34-41
pubmed: 30553401
J Am Soc Nephrol. 2001 Apr;12(4):791-799
pubmed: 11274240
N Engl J Med. 2019 Jan 3;380(1):23-32
pubmed: 30415637
J Atheroscler Thromb. 2014;21(3):248-60
pubmed: 24270918
Circ J. 2016;80(2):450-60
pubmed: 26667367
Eur Heart J. 2018 Jun 14;39(23):2192-2207
pubmed: 29897428
Atherosclerosis. 2015 Sep;242(1):357-66
pubmed: 26253795
Heart Vessels. 2019 May;34(5):755-762
pubmed: 30430295
Lancet. 2007 Mar 31;369(9567):1090-8
pubmed: 17398308
Atherosclerosis. 2011 Sep;218(1):110-6
pubmed: 21684546
N Engl J Med. 2012 Jul 26;367(4):309-18
pubmed: 22686415
Eur J Nutr. 2006 Feb;45(1):55-60
pubmed: 16041475
Am J Kidney Dis. 2009 Jun;53(6):982-92
pubmed: 19339088
Atherosclerosis. 2016 Jun;249:65-9
pubmed: 27065243
J Atheroscler Thromb. 2011;18(2):99-107
pubmed: 21099130
Circ J. 2012;76(2):423-9
pubmed: 22156311
Circ Rep. 2020 Mar 28;2(4):260-264
pubmed: 33693239
Heart Vessels. 2014 Nov;29(6):847-54
pubmed: 24212260
JAMA. 1998 Jan 7;279(1):23-8
pubmed: 9424039
Eur Heart J. 2019 Jan 14;40(3):226
pubmed: 30649367
J Atheroscler Thromb. 2018 Jul 1;25(7):593-605
pubmed: 29199200
Heart Vessels. 2018 May;33(5):481-488
pubmed: 29147787
Atherosclerosis. 2013 Dec;231(2):261-7
pubmed: 24267237
Stroke. 2013 Jul;44(7):2064-89
pubmed: 23652265
Circulation. 2003 Mar 18;107(10):1372-7
pubmed: 12642356
Adv Food Nutr Res. 2012;65:211-22
pubmed: 22361189
N Engl J Med. 2019 Jan 3;380(1):11-22
pubmed: 30415628
J Cardiol. 2017 Dec;70(6):537-544
pubmed: 28863874
JAMA. 2002 Apr 10;287(14):1815-21
pubmed: 11939867
Postgrad Med. 2019 May;131(4):268-277
pubmed: 31063407